Scientists remove amyloid plaques from brains of live animals with Alzheimer's disease

Oct 15, 2009

A breakthrough discovery by scientists from the Mayo Clinic in Jacksonville, FL, may lead to a new treatment for Alzheimer's Disease that actually removes amyloid plaques -- considered a hallmark of the disease -- from patients' brains. This discovery, published online in The FASEB Journal, is based on the unexpected finding that when the brain's immune cells (microglia) are activated by the interleukin-6 protein (IL-6), they actually remove plaques instead of causing them or making them worse. The research was performed in a model of Alzheimer's disease established in mice.

"Our study highlights the notion that manipulating the brain's could be translated into clinically tolerated regimens for the treatment of neurodegenerative diseases," said Pritam Das, co-author of the study, from the Mayo Clinic in Jacksonville, FL.

Das and colleagues made this unexpected discovery when they initially set out to prove that the activation of microgila trigger , making the disease worse. Their hypothesis was that microglia would attempt to remove the plaques, but would be unable to do so, and in the process cause excessive inflammation. To the surprise of the researchers, when microglia were activated by IL-6, they cleared the plaques from the brains.

To do this, the researchers over-expressed IL-6 in the brains of newborn mice that had yet to develop any amyloid plaques, as well in mice with pre-existing plaques. Using somatic transgenesis technology, scientists analyzed the effect of IL-6 on brain neuro-inflammation and plaque deposition. In both groups of mice, the presence of IL-6 lead to the clearance of from the brain. Researchers then set out to determine exactly how IL-6 worked to clear the plaques and discovered that the inflammation induced by IL-6 directed the microglia to express proteins that removed the plaques. This research suggests that manipulating the brain's own immune cells through inflammatory mediators could lead to new therapeutic approaches for the treatment of neurodegenerative diseases, particularly .

"This model is as close to human pathology as animal models get. These results give us an exciting lead to newer, more effective treatments of Alzheimer's disease," said Gerald Weissmann, M.D., Editor-in-Chief of The . "This study demonstrates that investment in experimental biology is the best way to approach the challenge posed by an aging population to the cost of health care."

More information: Paramita Chakrabarty, Karen Jansen-West, Amanda Beccard, Carolina Ceballos-Diaz, Yona Levites, Christophe Verbeeck, Abba C. Zubair, Dennis Dickson, Todd E. Golde, and Pritam Das. Massive gliosis induced by interleukin-6 suppresses A deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. doi:10.1096/fj.09-141754

Source: Federation of American Societies for Experimental Biology (news : web)

Explore further: Dual role: Key cell division proteins also power up mitochondria

add to favorites email to friend print save as pdf

Related Stories

Anti-inflammatory drug blocks brain plaques

Jun 24, 2008

Brain destruction in Alzheimer's disease is caused by the build-up of a protein called amyloid beta in the brain, which triggers damaging inflammation and the destruction of nerve cells. Scientists had previously shown that ...

Recommended for you

Proper stem cell function requires hydrogen sulfide

1 hour ago

Stem cells in bone marrow need to produce hydrogen sulfide in order to properly multiply and form bone tissue, according to a new study from the Center for Craniofacial Molecular Biology at the Herman Ostrow School of Dentistry ...

Bionic ankle 'emulates nature'

7 hours ago

These days, Hugh Herr, an associate professor of media arts and sciences at MIT, gets about 100 emails daily from people across the world interested in his bionic limbs.

Firm targets 3D printing synthetic tissues, organs

8 hours ago

(Medical Xpress)—A University of Oxford spin-out, OxSyBio, will develop 3D printing techniques to produce tissue-like synthetic materials for wound healing and drug delivery. In the longer term the company ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

superhuman
5 / 5 (1) Oct 16, 2009
Key information is missing here - did symptoms decline after removal of the plaques?

More news stories

Turning off depression in the brain

Scientists have traced vulnerability to depression-like behaviors in mice to out-of-balance electrical activity inside neurons of the brain's reward circuit and experimentally reversed it – but there's ...

Spate of Mideast virus infections raises concerns

A recent spate of infections from a frequently deadly Middle East virus is raising new worries about efforts to contain the illness, with infectious disease experts urging greater vigilance in combatting ...

Clean air: Fewer sources for self-cleaning

Up to now, HONO, also known as nitrous acid, was considered one of the most important sources of hydroxyl radicals (OH), which are regarded as the detergent of the atmosphere, allowing the air to clean itself. ...

Thinnest feasible nano-membrane produced

A new nano-membrane made out of the 'super material' graphene is extremely light and breathable. Not only can this open the door to a new generation of functional waterproof clothing, but also to ultra-rapid filtration. The ...

There's something ancient in the icebox

Glaciers are commonly thought to work like a belt sander. As they move over the land they scrape off everything—vegetation, soil, and even the top layer of bedrock. So scientists were greatly surprised ...